Price Chart

Profile

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.
URL http://www.editasmedicine.com
Investor Relations URL https://ir.editasmedicine.com
HQ State/Province Massachusetts
Sector Health Care
Industry Biotechnology
Next Earnings Release Mar. 11, 2026 (est.)
Last Earnings Release Nov. 10, 2025
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.
URL http://www.editasmedicine.com
Investor Relations URL https://ir.editasmedicine.com
HQ State/Province Massachusetts
Sector Health Care
Industry Biotechnology
Next Earnings Release Mar. 11, 2026 (est.)
Last Earnings Release Nov. 10, 2025
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A